# Thymosin Alpha-1: Research Overview — Peptide Biotechnology > A plain-English literature summary of Thymosin Alpha-1 (thymalfasin): TLR2/TLR9 immunomodulation mechanism, sepsis trial results, COVID-19 data, cancer immunotherapy context, and regulatory status. Part of Research Peptide Fundamentals. A 28-amino-acid thymic peptide that works at the innate-adaptive immune interface — promoting dendritic-cell maturation and T-cell activation while also generating regulatory signals to limit immune overreach. ## The short version **Thymosin Alpha-1** (also written Tα1, thymalfasin, or thymosin α-1) is a naturally occurring peptide cleaved from a protein called prothymosin alpha in the thymus — the gland that trains immune cells. The 28-amino-acid synthetic version is approved as a drug (thymalfasin) in more than 35 countries for conditions including chronic hepatitis B and C, but **not** in the United States. It is important to keep Thymosin Alpha-1 distinct from several related-sounding compounds it is often confused with: it is **not** thymulin (a different, zinc-dependent thymic nonapeptide), and it is **not** thymosin beta-4 or TB-500 (an entirely different protein with different sequence, targets and pharmacology). The naming overlap is a consistent source of confusion in popular discussion. The evidence base is clinically substantial in some areas but has significant limits. The compound's largest and most rigorous trial — a 1,106-patient Phase 3 sepsis study — found no significant 28-day mortality benefit [18]. Earlier smaller studies in sepsis showed more encouraging trends. The hepatitis and immune-restoration evidence is stronger [19]. This page summarizes what the published record actually shows. ## What it is Thymosin Alpha-1 is a 28-amino-acid N-terminally acetylated polypeptide (Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn). It is highly acidic — no aromatic residues, no disulfide bonds — and the N-terminal acetylation is essential for biological activity; removing it eliminates potency. In the body it is cleaved from the 113-amino-acid precursor prothymosin alpha, predominantly in thymic epithelial cells. The synthetic drug form, thymalfasin, is sequence-identical to the naturally occurring peptide. Internationally, thymalfasin is approved under various names for viral hepatitis and other immune-deficiency conditions. In the United States it has not received FDA marketing authorization; US use is investigational or through compounding, with regulatory questions remaining about bulk-substance eligibility. This is an entirely different compound from thymosin beta-4 (and its peptide fragment TB-500): different sequence, different source protein, different mechanism, different therapeutic applications. References to "thymosin" in research literature should always specify which thymosin. ## How it works: the immune-signaling mechanism Thymosin Alpha-1 acts at the *innate-adaptive immune interface* — the junction where the body's first-response cells (innate immunity: dendritic cells, monocytes, macrophages) hand off signals to the more specialized responders (adaptive immunity: T cells, B cells). The primary cellular targets are **dendritic cells and monocytes**, which carry the pattern-recognition receptors TLR2 and TLR9 on their surfaces. When Thymosin Alpha-1 engages these receptors, it promotes dendritic-cell maturation, upregulates antigen-presentation capability (including HLA-DR expression on monocytes), and stimulates production of interleukin-12 — a key signal that drives the adaptive response toward a Th1 (cell-mediated) orientation [21][22]. In practical terms this makes the immune system better at recognizing and attacking pathogens and abnormal cells. A counterbalancing mechanism operates through the IDO-tryptophan catabolism pathway, which generates regulatory T cells. This dual profile — restoring effector immunity in immunosuppressed states while simultaneously providing a regulatory brake — is the molecular basis for claims that Thymosin Alpha-1 can be both immunostimulatory and anti-inflammatory depending on context [21]. For severely immunocompromised patients (lymphocytopenic COVID-19, late-stage cancer, post-chemotherapy), the peptide's documented ability to increase circulating T-cell counts and reverse markers of T-cell exhaustion (reduced PD-1 and Tim-3 expression on CD8+ T cells) is a well-described effect in the evidence [20][21]. ## What the research shows **Comprehensive literature review (2020).** A broad review covering four decades of clinical literature establishes that thymalfasin is approved in more than 35 countries, that dosing in clinical studies ranged from 0.8 to 16 mg (multiple-dose regimens), and that it is generally well tolerated — the most common adverse effects being mild local injection-site reactions [19]. **COVID-19 retrospective cohort (2020, 76 patients).** In a retrospective review of patients with severe COVID-19, Thymosin Alpha-1 treatment was associated with significantly lower mortality (11.1% versus 30.0%, P=0.044), with the peptide increasing blood T-cell counts in lymphocytopenic patients and reducing PD-1 and Tim-3 expression on CD8+ T cells — markers of T-cell exhaustion [20]. This is retrospective, not randomized, and primarily relevant to a specific context of severe immune depletion. **Cancer immunotherapy context (2019, review).** A review positioned Thymosin Alpha-1 as a potential immunostimulatory adjuvant in cancer combination protocols — helping "turn a cold tumor hot" by activating dendritic cells and the adaptive immune response, and potentially reducing checkpoint-inhibitor toxicity through its regulatory arm [21]. This is a mechanistic and early-clinical framing, not an established oncology standard. **ETASS sepsis trial (2013, 361 patients).** In a multicenter randomized controlled trial in severe sepsis, 28-day all-cause mortality was 26.0% in the Thymosin Alpha-1 group versus 35.0% in controls — an approximately 9 percentage point difference. This result had marginal statistical significance (P=0.049 by log-rank, P=0.062 in the non-stratified analysis) and improved monocyte HLA-DR expression was observed [22]. **TESTS Phase 3 trial (2025, 1,106 patients) — null result.** The largest and most rigorous sepsis trial to date found no statistically significant difference in 28-day all-cause mortality between Thymosin Alpha-1 (23.4%) and placebo (24.1%): hazard ratio 0.99 (95% CI 0.77-1.27), P=0.93 [18]. This null result from a double-blind, placebo-controlled Phase 3 trial substantially qualifies earlier positive signals in the sepsis setting. ## Reported effects, cautions and safety **Anecdotal community reports** (anecdotal, not clinical evidence): The most commonly reported benefit in research-use community accounts is a reduced frequency or duration of common respiratory illnesses over a season — fewer or shorter colds, described as a perceived improvement in immune resilience. Faster recovery from lingering illness or run-down periods is frequently mentioned. A general sense of immune support is commonly described but is subjective and prone to expectation effects. Many users report feeling nothing unusual at all and describe it as one of the easier peptides to tolerate — consistent with its documented benign safety profile. Occasional short-lived flu-like or achy sensations early in a course are reported by some. The single most common adverse report is mild redness, itching or brief stinging at the injection site, resolving on its own. Significantly, some more informed community members note that the 2025 Phase 3 sepsis trial came back negative, tempering expectations for dramatic clinical effects outside the settings where evidence is strongest. **Literature-grounded cautions:** - Theoretical caution in established autoimmune disease: broadly restoring effector immunity in a setting of autoimmunity could in principle worsen immune dysregulation, though the peptide's regulatory IDO-arm counterbalances this mechanistically. - Theoretical caution in solid-organ transplant recipients on immunosuppression: restoring T-cell function and reversing T-cell exhaustion could work against intentional graft-protecting immunosuppression. - The TESTS Phase 3 trial was null; efficacy expectations in sepsis should be tempered accordingly [18]. - No dedicated pregnancy or lactation safety data exist in the published literature [19]. - Not FDA-approved for marketing in the United States; research-grade material from unregulated suppliers has no verified identity, purity or sterility. ## Where it fits in Research Peptide Fundamentals Thymosin Alpha-1 represents the **immune class** on this desk — a peptide whose primary action is not tissue repair, hormone secretion or metabolic signaling but the calibration of immune-cell behavior. Among the four peptides covered here, it is the one with the most clinical trial history (decades across hepatitis, sepsis, cancer and COVID-19 contexts) and the broadest international regulatory approval — yet also the one where a large Phase 3 trial most recently challenged the optimistic interpretation of earlier evidence. Compared with [BPC-157](/bpc-157), which promotes structural repair through angiogenesis, Thymosin Alpha-1 works entirely in the immune compartment. Compared with [Ipamorelin](/ipamorelin), whose primary axis is the somatotropic (GH/IGF-1) system, Thymosin Alpha-1 touches a completely different physiological domain. Compared with [Retatrutide](/retatrutide), which modulates energy metabolism through incretin receptors, Thymosin Alpha-1 has no established metabolic mechanism. Its position here underlines the range of signaling biology the peptide field covers — from vessel growth to pituitary pulses to fat mobilization to T-cell education. See the [compare](/compare) page for a structured side-by-side. --- A desk for reading, not prescribing — literature summaries of research peptide biology, cited to the primary source.